Effects of 1 year of daily teriparatide treatment on iliacal bone mineralization density distribution (BMDD) in postmenopausal osteoporotic women previously treated with alendronate or risedronate.

In osteoporotic women, teriparatide increased cancellous mineralization heterogeneity by 10.7% from baseline.

In plain wordsIn women with osteoporosis, teriparatide increased cancellous mineralization variation from baseline.

Measurements

Cancellous mineralization heterogeneity change (Cn.Ca(Width))

10.7%

pooled groups, change from baseline

Source sentences

In osteoporotic women, teriparatide increased cortical mineralization heterogeneity by 19.6% from baseline.

In plain wordsIn women with osteoporosis, teriparatide increased cortical mineralization variation from baseline.

Measurements

Cortical mineralization heterogeneity change (Ct.Ca(Width))

19.6%

pooled groups, change from baseline

Source sentences

In osteoporotic women, teriparatide increased cancellous low-mineralized bone area by 18.2% from baseline.

In plain wordsIn women with osteoporosis, teriparatide increased cancellous low-mineralized bone area from baseline.

Measurements

Change in pooled cancellous low-mineralized bone area (Cn.Ca(Low)) from baseline

18.2%

Pooled priorALN and priorRIS women, 12 months of teriparatide

Source sentences

In osteoporotic women, teriparatide increased cortical low-mineralized bone area by 36.6% from baseline.

In plain wordsIn women with osteoporosis, teriparatide increased cortical low-mineralized bone area from baseline.

Measurements

Change in pooled cortical low-mineralized bone area (Ct.Ca(Low)) from baseline

36.6%

Pooled priorALN and priorRIS women, 12 months of teriparatide

Source sentences

In women previously given alendronate, teriparatide increased cancellous low-mineralized bone area by 25.9% from baseline.

In plain wordsIn women previously given alendronate, teriparatide increased cancellous low-mineralized bone area from baseline.

Measurements

Cancellous low-mineralized area change (Cn.Ca(Low))

25.9%

priorALN, change from baseline

Source sentences

In women previously given alendronate, teriparatide increased cortical low-mineralized bone area by 62.0% from baseline.

In plain wordsIn women previously given alendronate, teriparatide increased cortical low-mineralized bone area from baseline.

Measurements

Cortical low-mineralized area change (Ct.Ca(Low))

62%

priorALN, change from baseline

Source sentences

In women previously given alendronate, teriparatide increased cortical mineralization heterogeneity by 22.8% from baseline.

In plain wordsIn women previously given alendronate, teriparatide increased cortical mineralization variation from baseline.

Measurements

Cortical mineralization heterogeneity change (Ct.Ca(Width))

22.8%

priorALN, change from baseline

Source sentences

In women previously given risedronate, teriparatide increased cancellous mineralization heterogeneity by 14.8% from baseline.

In plain wordsIn women previously given risedronate, teriparatide increased cancellous mineralization variation from baseline.

Measurements

Cancellous mineralization heterogeneity change (Cn.Ca(Width))

14.8%

priorRIS, change from baseline

Source sentences

In women previously given risedronate, teriparatide increased cortical mineralization heterogeneity by 15.8% from baseline.

In plain wordsIn women previously given risedronate, teriparatide increased cortical mineralization variation from baseline.

Measurements

Cortical mineralization heterogeneity change (Ct.Ca(Width))

15.8%

priorRIS, change from baseline

Source sentences